Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-CEED: Azetukalner in Bipolar Depression
NCT07172516Phase 3Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Azetukalner with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07172516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172516.